Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D

doi:10.3748/wjg.v17.i45.4987

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3609)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

298

HTML

3060

Tables (1-3)

251

Sum=3609

Dec 7, 2011 (publication date) through Nov 19, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 7, 2011; 17(45): 4987-4992
Published online Dec 7, 2011. doi: 10.3748/wjg.v17.i45.4987

Table 1 Demographic features of study patients

	Chronic hepatitis B	Inactive HBsAg carriers	P value
No. of patients, n (%)	245 (86.6)	38 (13.4)
Sex (male/female)	166/79	11/27	0.852
BMI (mean ± SD, kg/m²)	25.9 ± 4.3	25.7 ± 3.6	0.914
Hemoglobin (mean ± SD, gr/dL)	14.9 ± 1.5	14.9 ± 1.6	0.949
White cell count (mean ± SD, /mm³)	6577 ± 1783	6615 ± 1599	0.959
Thrombocyte count (mean ± SD, 1000/mm³)	200 482 ± 57 762	219 727 ± 63 743	0.088
AST (mean ± SD, IU/L)	56.2 ± 51.3	25.2 ± 11.1	0.000
ALT (mean ± SD, IU/L)	91.6 ± 92.6	25.3 ± 13.2	0.000
HBeAg positivity, n (%)	57 (23.2)	0
HBV DNA (mean ± SD copies/mL)	4.9 × 10⁸± 5.9 × 10⁹	2.0 × 10³± 2.6 × 10³	0.000
Histopathological findings, n¹:143
Total HAI score, median (range)	7 (1-18)
PN and BN, median (range)	2 (0-7)
ID and FN, median (range)	1 (0-4)
PI, median (range)	2 (0-4)
Fibrosis, median (range)	2 (0-4)

¹Number of patients who underwent liver biopsy. BMI: Body mass index; HAI: Histological activity index; PN: Piecemeal necrosis; BN: Bridging necrosis; ID: Intralobular degeneration; FN: Focal necrosis; PI: Portal inflammation; HBV: Hepatitis B virus; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

Table 2 Levels of hepatitis B virus DNA and alanine aminotransferase in chronic hepatitis B by HBeAg positivity

	HBeAg-positive (n = 57)			HBeAg-negative (n = 210)			P value
	Min	Max	mean ± SD	Min	Max	mean ± SD
ALT (IU/L)	17	537	121.6 ± 120.3	7	423	81.9 ± 77.4	0.012
HBV DNA (copies/mL)	1 × 10⁴	9.3 × 10¹⁰	1.7 × 10⁹± 1.2 × 10¹⁰	1 × 10⁴	1.4 × 10⁹	1 × 10⁸± 2.3 × 10⁸	0.15

ALT: Alanine aminotransferase; HBV: Hepatitis B virus.

Table 3 Rates of tyrosine-methionine-aspartate-aspartate mutation in patients with chronic hepatitis B virus infection n (%)

	Chronic hepatitis B			Inactive HBsAg carriers	Total
Previous lamivudine treatment		Total
Yes¹	No
YVDD + YIDD positive	17 (53.1)	Total	8 (4)	25 (10.7)	1 (3)	26 (9.7)
YMDD negative	15 (46.9)	194 (96)	209 (89.3)	32 (97)	241 (90.3)
Total	32	202	234	33	267

¹Patients who are receiving or received lamivudine previously. YMDD: Tyrosine-methionine-aspartate-aspartate; YIDD: Tyrosine-isoleucine-aspartate-aspartate; YVDD: Tyrosine-valine-aspartate-aspartate.

Citation: Yıldız O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yıldırmak T, Kantürk A, Tütüncü E, Group HBS. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17(45): 4987-4992
URL: https://www.wjgnet.com/1007-9327/full/v17/i45/4987.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i45.4987